THIS WEEK'S FEATURE

This Week's Feature

MIRA advancing marijuana 2.0 for anxiety, cognitive decline, pain in seniors

MIRA Pharmaceuticals (NASDAQ:MIRA) is developing MIRA1a, a novel synthetic analog of THC (tetrahydrocannabinol) to treat anxiety and cognitive decline in the elderly and neuropathic pain, with a lower impurity profile...

September 19, 2023

MORE FEATURES

Feature

Avenue Therapeutics focused on 3 near-term assets for neurologic diseases

Avenue Therapeutics (NASDAQ:ATXI) has taken a quantum leap into the CNS space during landscape over the past 12 months by adding two early-stage clinical assets to its pipeline to complement its late-stage intravenous...

September 12, 2023

Feature

Glyscend pioneering new class of GI-targeted therapy for T2D and obesity

Closely-held Glyscend Therapeutics is developing an orally administered, gut-restricted drug for Type 2 diabetes and obesity, based on “duodenal exclusion” physiology, a key mechanism of gastric bypass surgery.

September 5, 2023

Feature

Convergent readies IND for next-gen targeted radiotherapy

Closely-held Convergent Therapeutics is rapidly advancing a next generation alpha-emitting prostate-specific membrane antigen (PSMA)-targeted radioantibody for an IND filing in October.

August 29, 2023